Calprotectin is an established biomarker for assisting with differentiating IBD from IBS and can therefore exclude IBS patients from unnecessary colonoscopies allowing for more timely IBD identification and treatment.
With a clinical cut-off of 50 µg/g, the STELLUX® Chemi Calprotectin ELISA boasts clinical specificity of >95% when differentiating IBD from IBS. The assay’s broad range of 7.9 – 10,000 µg/g eliminates sample reruns. When used with the Easy Stool Extraction Device, sample processing time is reduced by up to 86%. Furthermore, robust quality control ensures confidence in data without concern for assay drift over time.
*Final labeling and performance claims are pending FDA 510(k) Premarket Notification submission and clearance.